Company Overview and News

 
PetGas bottom line increases to RM483mil

2018-05-17 thestar.com.my
PETALING JAYA: Petronas Gas Bhd (PetGas) recorded a 4.3%-higher bottom line at RM483.22mil in the first quarter ended March 31, largely on the back of its stronger revenue.

 
Petronas Gas earnings higher in Q1

2018-05-17 thestar.com.my
Petronas Gas declared an interim dividend of 16 sen a share compared with 15 sen a year ago.

 
KLCI closes down 18pts as Maxis, CIMB and Maybank weigh

2018-05-02 thestar.com.my
KUALA LUMPUR: Blue chips closed on a weak note on Wednesday ahead of the 14th General Election on May 9 as investors decided to stay on the sidelines. At 5pm, the FBM KLCI was down 18.34 points or 0.98% to 1,852.03. Turnover was 2.10 billion shares valued at RM2.43bil. There were 311 gainers, 551 losers and 381 counters unchanged. Hong Kong stocks fell as investors braced for trade talks between US and Chinese officials, and awaited the US Federal Reserve's upcoming policy statement, Reuters reported.

 
Bursa Malaysia stays higher at mid-morning

2018-03-30 themalaymailonline
At 11.10am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) was trading at 1,861.28, up 4.93 points from Thursday’s close of 1,856.35. — Picture by Azneal IshakKUALA LUMPUR, March 30 ― Bursa Malaysia stayed higher at mid-morning today on persistent buying interest in selected heavyweights, dealers said.

 
KLCI slightly higher on Digi, banks at midday

2018-03-19 thestar.com.my
KUALA LUMPUR: Some fund buying of Digi and selected banks helped underpin the FBM KLCI's gains at midday but the broader market was cautious.

 
Bursa ends lower on rampant profit-taking

2018-03-14 themalaymailonline
KUALA LUMPUR, March 14 — Bursa Malaysia closed lower today, echoing global and regional equity performances on rampant profit-taking, leaving the indices in the red throughout the day, dealers said.

 
Bursa stays higher at mid-morning

2018-02-27 themalaymailonline
Market breadth was slightly negative as losers led gainers 391 to 363, while 396 counters remained unchanged, 733 untraded and 52 others suspended. — Picture Ahmad ZamzahuriKUALA LUMPUR, Feb 27 — Bursa Malaysia remained higher at mid-morning today and amid persistent buying interest in selected blue-chip finance stocks and heavyweights.

 
Bursa mixed at mid-afternoon

2018-02-26 themalaymailonline
On the broader market, losers outpaced gainers by 453 to 434, while 408 counters were unchanged, 600 untraded and 64 others suspended. — Reuters picKUALA LUMPUR, Feb 26 — Bursa Malaysia turned mixed at mid-afternoon today, with the benchmark index in positive territory lifted by the finance counters.

 
Bursa Malaysia broadly higher at mid-day

2018-02-19 themalaymailonline
At 12.30pm, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) rose 16.09 points at 1,854.37 from last Thursday’s close of 1,838.28. — Picture Ahmad ZamzahuriKUALA LUMPUR, Feb 19 ― Bursa Malaysia ended broadly higher at mid-day today, with strong buying interest across-the-board, led by index linked blue chips, Petronas Gas and Genting Bhd, dealers said.

 
Diary Malaysia 2018 corporate earnings

2018-02-19 thestar.com.my
KUALA LUMPUR: Following is a list of release dates for the quarterly earnings of some top Malaysia-listed companies.

 
Bursa ends week in the red across the board

2018-02-09 themalaymailonline
Losers led gainers by 900 to 208, while 312 counters were unchanged, 438 untraded and 31 others suspended. — Picture Ahmad ZamzahuriKUALA LUMPUR, Feb 9 — Bursa Malaysia finished the week in the red across-the-board today, tracking the global stock sell-off following another day of overnight Wall Street losses, dealers said.

 
Harrowing week for equities, KLCI closes down nearly 20pts on Friday

2018-02-09 thestar.com.my
KUALA LUMPUR: Global equities markets had a harrowing week from the fallout on Wall Street and Bursa Malaysia also saw investor sentiment battered while the ringgit lost ground. At 5pm, the KLCI was down 19.62 points or 1.07% to 1,819.82 while its year-to-date gains have whittled to 1.28%. Turnover declined to 2.45 billion shares valued at RM2.67bil.  The broader market continued to stay cautious with decliners beating advancers nine to two or 900 losers to 208 gainers and 312 counters unchanged.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...